Anti-CD3 recombinant antibody [UCH-T1®]

Contributors

Inventor Institute
Peter Beverley Cancer Research, UK London Research Institute: Lincoln's Inn Fields
SKU: 152589
Product description: Recombinant version of CRT trademarked famous anti-CD3 monoclonal antibody, capable of differentiating between T vs B cells lymphomas and leukaemias. Background and Research Application The CD3 complex, composed of four distinct CD3 polypeptide chains ( CD3gamma, CD3omega and 2X CD3epsilon), associates with the T cell antigen receptor (TCR). It is found on all mature human T lymphocytes, NK cells and some thymocytes. CD3 is a member of the immunoglobulin superfamily, involved in antigen recognition, T lymphocyte activation and signal transduction. This is a recombinant version of anti-CD3 UCH-T1 . UCH-T1 is considered a pan T-cell marker – it can be used for the detection of T cell populations in peripheral blood and lymph nodes and the categorisation of T versus B cell lymphomas and leukaemias. It reacts with the majority of peripheral blood T lymphocytes, a major proportion of thymocytes, the majority of T cell chronic lymphocytic leukaemia cells, Sezary leukaemias and approximately 70% of acute lymphoblastic leukaemias of T cell origin. It can also be used to study the role of CD3 in TCR signal transduction events. This antibody was created by Professor Peter Beverley, a pioneer in creating hybridomas from mice immunised against human lymphocytes, with UCHT1 being one of the first successful fusions.
Additional notes: UCH-T1® is a registered trademark of Cancer Research Technology, Limited. All rights reserved.
Conjugation: Unconjugated
Isotype: IgG1
Immunogen: Human infant thymocytes and Sezary cells.
Immunogen Uniprot ID: P04234
Cat. #: 152589
Tool sub type: Primary antibody
Unit size: 100 ug
Application: FACS ; WB
Target: CD3
Reactivity: Human
Clone: rUCH-T1
Host: Mouse
Class: Recombinant
Target background: Recombinant version of CRT trademarked famous anti-CD3 monoclonal antibody, capable of differentiating between T vs B cells lymphomas and leukaemia’s.Background and Research Application The CD3 complex, composed of four distinct CD3 polypeptide chains (CD3γ, CD3δ and 2X CD3Ɛ), associates with the T cell antigen receptor (TCR). It is found on all mature human T lymphocytes, NK cells and some thymocytes. CD3 is a member of the immunoglobulin superfamily, involved in antigen recognition, T lymphocyte activation and signal transduction.This is a recombinant version of anti-CD3 UCH-T1. UCH-T1 is considered a pan T-cell marker – it can be used for the detection of T cell populations in peripheral blood and lymph nodes and the categorisation of T versus B cell lymphomas and leukaemia’s. It reacts with the majority of peripheral blood T lymphocytes, a major proportion of thymocytes, the majority of T cell chronic lymphocytic leukaemia cells, Szary leukaemia’s and approximately 70% of acute lymphoblastic leukaemia’s of T cell origin. It can also be used to study the role of CD3 in TCR signal transduction events.This antibody was created by Professor Peter Beverley, a pioneer in creating hybridomas from mice immunised against human lymphocytes, with UCHT1 being one of the first successful fusions.
Format: Liquid
Concentration: 1 mg/ml
Storage buffer: PBS only
Storage conditions: Store at -20 C frozen. Avoid repeated freeze / thaw cycles
Shipping conditions: Dry ice
References:

Original hybridoma first published in: Beverley et al. 1981. Eur J Immunol. 11(4):329-34. PMID: 6788570.

Distinctive Fn characteristics of human "T" lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody.

Images

View Gallery
Flowcytometric analysis of the dose-dependency (D; F; H) of anti-hCD3e antibody binding to live human PBMCs (B). The gating strategy is shown for control puposes (A; B; C; E; G).

Related Tools for Antibodies

Cat. # Tool Name
151175 Anti-CD3 monoclonal antibody [UCH-T1®] Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.